These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16010858)

  • 21. Evaluation and suggested improvements of the Biopharmaceutics Classification System (BCS).
    Fagerholm U
    J Pharm Pharmacol; 2007 Jun; 59(6):751-7. PubMed ID: 17637167
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Implementing the Biopharmaceutics Classification System in Drug Development: Reconciling Similarities, Differences, and Shared Challenges in the EMA and US-FDA-Recommended Approaches.
    Cardot JM; Garcia Arieta A; Paixao P; Tasevska I; Davit B
    AAPS J; 2016 Jul; 18(4):1039-46. PubMed ID: 27116020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biowaiver monographs for immediate-release solid oral dosage forms: stavudine.
    Silva AL; Cristofoletti R; Storpirtis S; Sousa VD; Junginger HE; Shah VP; Stavchansky S; Dressman JB; Barends DM
    J Pharm Sci; 2012 Jan; 101(1):10-6. PubMed ID: 21922462
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The role of biopharmaceutical parameters in drug development (author's transl)].
    Thoma K
    Arzneimittelforschung; 1976; 26(1A):121-9. PubMed ID: 947191
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension.
    Lennernäs H; Abrahamsson B
    J Pharm Pharmacol; 2005 Mar; 57(3):273-85. PubMed ID: 15807982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PBPK models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
    Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Importance of biopharmaceutics and pharmacokinetics in clinical medicine.
    Cabana BE
    Arzneimittelforschung; 1976; 26(1A):151-8. PubMed ID: 947194
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medicines for Pediatric Patients-Biopharmaceutical, Developmental, and Regulatory Considerations.
    Elder DP; Holm R; Kuentz M
    J Pharm Sci; 2017 Apr; 106(4):950-960. PubMed ID: 28041968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Basics of Sterile Compounding: Biopharmaceutics of Injectable Dosage Forms.
    Akers MJ
    Int J Pharm Compd; 2017; 21(1):47-56. PubMed ID: 28346198
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biowaiver monographs for immediate release solid oral dosage forms: furosemide.
    Granero GE; Longhi MR; Mora MJ; Junginger HE; Midha KK; Shah VP; Stavchansky S; Dressman JB; Barends DM
    J Pharm Sci; 2010 Jun; 99(6):2544-56. PubMed ID: 19960529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro-in vivo correlations: tricks and traps.
    Cardot JM; Davit BM
    AAPS J; 2012 Sep; 14(3):491-9. PubMed ID: 22547350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatrics Formulation Initiative: proceedings from the Second Workshop on Pediatric Formulations.
    Giacoia GP; Taylor-Zapata P; Zajicek A
    Clin Ther; 2012 Nov; 34(11):S1-10. PubMed ID: 23149008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bioavailability: some pharmaceutical factors.
    Fowle AS
    Trans Med Soc Lond; 1975; 91():23-32. PubMed ID: 1236035
    [No Abstract]   [Full Text] [Related]  

  • 34. Impact of the US FDA "Biopharmaceutics Classification System" (BCS) Guidance on Global Drug Development.
    Mehta MU; Uppoor RS; Conner DP; Seo P; Vaidyanathan J; Volpe DA; Stier E; Chilukuri D; Dorantes A; Ghosh T; Mandula H; Raines K; Dhanormchitphong P; Woodcock J; Yu LX
    Mol Pharm; 2017 Dec; 14(12):4334-4338. PubMed ID: 29076742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Bioavailability of raubasine in various pharmaceutical forms in the dog].
    Castoldi D; Chinea B; Montanari P
    Farmaco Prat; 1976 Nov; 31(11):580-5. PubMed ID: 1017471
    [No Abstract]   [Full Text] [Related]  

  • 36. [In vitro and in vivo biopharmaceutical evaluation of lorazepam commercial tablets].
    Giannone I; Musumeci T; Pecora TM; Puglisi G
    Clin Ter; 2005; 156(5):197-201. PubMed ID: 16382968
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Keeping a critical eye on the science and the regulation of oral drug absorption: a review.
    Macheras P; Karalis V; Valsami G
    J Pharm Sci; 2013 Sep; 102(9):3018-36. PubMed ID: 23568812
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Physiologically Based Absorption Modeling to Impact Biopharmaceutics and Formulation Strategies in Drug Development-Industry Case Studies.
    Kesisoglou F; Chung J; van Asperen J; Heimbach T
    J Pharm Sci; 2016 Sep; 105(9):2723-2734. PubMed ID: 26886317
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Bioavailability, proof of efficacy and their consequences for drug legislation (author's transl)].
    Schnieders B
    Arzneimittelforschung; 1976; 26(1A):158-63. PubMed ID: 947195
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The general problem of drug bioavailability and its assessment in man.
    Smith RN
    Postgrad Med J; 1974 Nov; 50 Suppl 6():7-14. PubMed ID: 4459894
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.